Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women

Gynecological Endocrinology

Volumn 18, Issue 3, 2004, Pages 152-158

  Komi, J ^a   Heikkinen, J ^b   Rutanen, E M ^c   Halonen, K ^a   Lammintausta, R ^a   Ylikorkala, O ^c  

^a Hormos Medical Ltd   (Finland)

^b OULU DEACONESS INSTITUTE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bone turnover; FC 1271a; Ospemifene; Osteoporosis; Postmenopausal; SERM

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; OSPEMIFENE; PEPTIDE DERIVATIVE; PHOSPHATASE; PLACEBO; PROCOLLAGEN TYPE 1 C PROPEPTIDE; PROCOLLAGEN TYPE 1 N PROPEPTIDE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TELOPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; MEASUREMENT; METHODOLOGY; NORMAL HUMAN; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; URINE VOLUME;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PLACEBOS; POSTMENOPAUSE; PROCOLLAGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 1542267719     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590410001672197     Document Type: Article

References (24)

1. Melton LJ 3rd, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10
2. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117: 1016-37
3. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
4. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
5. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 1999;282:637-45
6. Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000;109:267-76
7. Wells G, Tugwell P, Shea B, et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-39
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288:321-33
9. Saitta A, Morabito N, Frisina N, et al. Cardiovascular effects of raloxifene hydrochloride. Cardiovasc Drug Rev 2001;19:57-74
10. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809-20
11. Qu Q, Härkonen PL, Väänänen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 1999;73:500-7
12. Parikka V, Lehenkari PP, Härkönen PL, et al. The effect of two selective estrogens raloxifene and FC1271a on osteoclast survival and resorption in vitro. J Bone Miner Res 1998;23:S552
13. Voipio SK, Komi J, Kangas L, et al. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43: 207-14
14. Rutanen E-M, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and on quality of life in postmenopausal women: a double-blind randomized trial. Menopause 2003;10:433-9
15. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11:S2-17
16. Delmas PD. Markers ofbone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000;11:S66-76
17. Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy postmenopausal women. Menopause 2003;10:440-7
18. Simberg N, Tiitinen A, Silfvast A, et al. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement. J Clin Endocrinol Metab 1996;81:646-51
19. Marttunen MB, Hietanen P, Tiitinen A, et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998;83:1158-62
20. Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79:1693-700
21. Chesnut CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37
22. Peacock M, Liu G, Carey M, et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000;85:3011-19
23. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337: 1641-7
24. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-54